Progress in brain penetration evaluation in drug discovery and development

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 349-356

  Liu, Xingrong ^a   Chen, Cuiping ^b   Smith, Bill J ^c  

^a ROCHE BIOSCIENCE   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CETIRIZINE; CYCLOSPORIN; GLYCOPROTEIN P; LOPERAMIDE; METHADONE; MITOXANTRONE; QUINIDINE; CENTRAL NERVOUS SYSTEM AGENTS;

BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DRUG INHIBITION; DRUG PENETRATION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; WESTERN BLOTTING; ANIMAL; DRUG DESIGN; METABOLISM; PERMEABILITY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DESIGN; HUMANS; P-GLYCOPROTEINS; PERMEABILITY;

EID: 42449100856     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.130294     Document Type: Review

References (58)

1. Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M, and Phebus LA (2006) Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci 78:3007-3012.
2. Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, and Miller DS (2006) In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70:1212-1219.
3. Becker S and Liu X (2006) Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos 34:855-861.
4. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JHM (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of Breast Cancer Resistance Protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582.
5. Chen C, Hanson E, Watson JW, and Lee JS (2003) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31:312-318.
6. Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
7. Cserr HF and Patlak CS (1993) Secretion and bulk flow of interstitial fluid, in Physiology and Pharmacology of the Blood-Brain Barrier (Bradbury MWB ed) pp 246-253, Springer, New York.
8. Dagenais C, Rousselle C, Pollack GM, and Scherrmann J-M (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386.
9. Dallas S, Miller DS, and Bendayan R (2006) Multidrug resistance- associated proteins: expression and function in the central nervous system. Pharmacol Rev 58:140-161.
10. Davson H and Segal MB (1995) Physiology of the CSF and Blood-Brain Barriers, CRC Press, Inc., Boca Raton, FL.
11. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174.
12. el-Bacha RS and Minn A (1999) Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol 45:15-23.
13. Fang J (2000) Metabolism of clozapine by rat brain: the role of flavin-containing monooxygenase (FMO) and cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet 25:109-114.
14. Feng B, Mills J, Davidson R, Mireles R, Janiszewski J, Troutman M, and de Morais S (2008) In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268-275.
15. Fridén M, Gupta A, Antonsson M, Bredberg U, and Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719.
16. Gervasini G, Carrillo JA, and Benitez J (2004) Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin Pharmacokinet 43:693-706.
17. Gratton J, Abraham M, Bradbury M, and Chadha H (1997) Molecular factors influencing drug transfer across the blood-brain barrier. J Pharm Pharmacol 49:1211-1216.
18. Gupta A, Hammarlund-Udenaes M, Chatelain P, Massingham R, and Jonsson EN (2006) Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. Biopharm Drug Dispos 27:291-297.
19. Hammarlund-Udenaes M, Paalzow LK, and de Lange EC (1997) Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method. Pharm Res 14:128-134.
20. Hansen DK, Scott DO, Otis KW, and Lunte SM (2002) Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. J Pharm Biomed Anal 27:945-958.
21. Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, Vaalburg W, and Franssen EJ (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418.
22. Hoffmann K, Gastens AM, Volk HA, and Löscher W (2006) Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res 69:1-14.
23. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, and Unadkat JD (2006) Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 317:704-710.
24. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, and Sugiyama Y (2007) Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71:619-627.
25. Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, and Yokoi T (2006) Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci 95:2673-2683.
26. Kusuhara H and Sugiyama Y (2005) Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73-85.
27. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, and Sugiyama Y (2005) Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312:44-52.
28. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621.
29. Liu X and Chen C (2005) Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Devel 8:505-512.
30. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313:1254-1262.
31. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34:1443-1447.
32. Liu X, Tu M, Kelly RS, Chen C, and Smith BJ (2004) Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos 32:132-139.
33. Liu X, Yeo H, Yau A, Van Natta K, Vilenski O, and Weller P (2007) Brain unbound drug concentration calculated from in vitro brain unbound fraction is consistent with brain extracellular fluid drug concentration measured by brain microdialysis for four model compounds. AAPS J 9:T2439.
34. Marchetti S, Mazzanti R, Beijnen JH, and Schellens JH (2007) Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12:927-941.
35. Maurer TS, Debartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
36. Pardridge W (2004) Log(BB), PS products and in silico models of drug brain penetration. Drug Discov Today 9:392-393.
37. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, and Serabjit-Singh CJ (2003) P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec®), a second-generation non-sedating antihistamine. J Pharm Sci 92:2082-2089.
38. Potschka H, Fedrowitz M, and Loscher W (2003) Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306:124-131.
39. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, and Piwnica-Worms D (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96:3900-3905.
40. Raub T (2006) P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 3:3-25.
41. Sadeque A, Wandel C, and He H (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
42. Santaguida S, Janigro D, Hossain M, Oby E, Rapp E, and Cucullo L (2006) Side by side comparison between dynamic versus static models of blood- brain barrier in vitro: a permeability study. Brain Res 1109:1-13.
43. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, and Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503-514.
44. Schinkel A and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
45. Shen DD, Artru AA, and Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825-1857.
46. Strazielle N, Khuth ST, and Ghersi-Egea JF (2004) Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv Drug Deliv Rev 56:1717-1740.
47. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, and Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205-213.
48. Suzuyama N, Katoh M, Takeuchi T, Yoshitomi S, Higuchi T, Asashi S, and Yokoi T (2007) Species differences of inhibitory effects on P-glycoprotein- mediated drug transport. J Pharm Sci 96:1609-1618.
49. Syvänen S, Xie R, Sahin S, and Hammarlund-Udenaes M (2006) Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res 23:705-717.
50. Takasato Y, Rapoport SI, and Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol Heart Circ Physiol 247:H484-H493.
51. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, and Schinkel AH (2003) The breast cancer resistance protein Bcrp1/Abcg2 restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo4,5-b pyridine. Cancer Res 63:6447-6452.
52. van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, and Schinkel AH (2006) Breast cancer resistance protein Bcrp1/Abcg2 reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27:123-130.
53. Wijnholds J, de Lange E, Scheffer G, van den Berg D-J, Mol C, van der Valk M, Schinkel AH, Scheper R, Breimer D, and Borst P (2000) Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105:279-285.
54. Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, Crespi CL, Miwa G, and Gan L-S (2006) Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using ATPase activity assays. Mol Pharm 3:78-86.
55. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for P-glycoprotein- mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.
56. Yousif S, Marie-Claire C, Roux F, Scherrmann JM, and Decleves X (2007) Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 1134:1-11.
57. Zhang L, Strong JM, Qiu W, Lesko LJ, and Huang S-M (2006a) Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3:62-69.
58. Zhang Y, Li CS, Ye Y, Johnson K, Poe J, Johnson S, Bobrowski W, Garrido R, and Madhu C (2006b) Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability. Drug Metab Dispos 34:1935-1943.